Houston VA lung cancer screening program saves lives
“Less than two years in, an innovative lung cancer screening program at the Michael E. DeBakey VA Medical Center in Houston is already saving Veterans’ lives. Since its launch in May 2021, the Lung Precision Oncology Program (LPOP) at the hospital has made 30 lung cancer diagnoses, more than 90% of which were found in the early stage, when it is most curable.”

US newspaper articles on lung cancer screening over last 10 years mostly positive
“More than three-fourths of newspaper articles on lung cancer screening published from 2010 to 2022 had a positive sentiment, according to study results published in American Journal of Roentgenology.”

Lurbinectedin Is Cost-Effective as a Second-Line Treatment in SCLC
“Treatment with lurbinectedin is cost-effective as a second-line treatment for patients with metastatic small cell lung cancer who have had disease progression on or after platinum-based chemotherapy.”

People Diagnosed With Lung Cancer Who Quit Smoking Early Have Better Lung Cancer Survival Rates
“Findings confirm that no matter how old you are, you should quit smoking, experts say.”

Turquoise Takeover: Stand Up Against Lung Cancer During PA’s Action Week
“PENNSYLVANIA, PA — This week, the American Lung Association is turning Pennsylvania turquoise to raise awareness of lung cancer and encourage residents to take action to end the disease during Lung Cancer Action Week (May 8-14). It is estimated that 11,320 Pennsylvanians will be diagnosed in 2023 alone and every day nationally, lung cancer takes the lives of more than 5,720 of our friends, neighbors and loved ones.”

Novel AI Model Offers Potential for Earlier Lung Cancer Diagnoses
“A new artificial intelligence (AI) model could help physicians diagnose lung cancer earlier, according to a study published by Hunter et al in eBioMedicine. The findings suggested that the new model may yield a diagnosis more quickly and potentially more accurately than two existing risk assessment scores.”

Are incidental findings on lung cancer screening getting flagged?
“May 4, 2023 — Incidental findings on low-dose CT (LDCT) lung cancer screening are relatively common. But are they being flagged — and followed up — appropriately? Perhaps not, if a recent study involving U.S. military veterans is any indication.”

American Lung Association and Gateway for Cancer Research to Co-Fund Lung Cancer Vaccine Trial
“An alliance between the American Lung Association (ALA) and Gateway for Cancer Research, a nonprofit organization funding early phase clinical trials, will provide $678,000 of funding for a five-year vaccine trial targeting small cell lung cancer (SCLC).”

FDA Approves FoundationOne Liquid CDx for Mobocertinib in NSCLC
“The FDA has approved the FoundationOne Liquid CDx assay as a companion diagnostic for identifying patients who may be eligible for treatment with mobocertinib (Exkivity) for locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations that has progressed on or following platinum-based chemotherapy, according to a press release from Foundation Medicine.”

Dr Jason Porter Provides an Overview of the Current Treatment Landscape for Small Cell Lung Cancer
“Jason Porter, MD, medical oncologist and hematologist, West Cancer Center and Research Institute, Memphis, Tennessee, defines small cell lung cancer and the risk factors associated with it. With smoking as a major risk factor, diagnosis for small cell lung cancer is rare compared with non–small cell lung cancer and varies widely by region in the United States.”

LUCAS recognized with White Ribbon from Breathe BioMedical
“MORGANTOWN, W.Va. – The WVU Cancer Institute Mobile Cancer Screening Program recently received a White Ribbon from Breathe BioMedical for LUCAS, a first of its kind, state-of-the-art mobile lung cancer screening unit.”

Immunotherapy plus chemotherapy combination for advanced lung cancer not only prolongs life but also improves its quality
“Phase 3 clinical trial reveals multiple benefits of cemiplimab plus platinum chemotherapy.”